IP Library › Granted Patent US 11,473,059
Granted Patent B2
US 11,473,059 · App. 15/769,872 · Granted Oct 18, 2022

Method for enrichment and expansion of virus antigen-specific T cells

Inventors: Seok Goo Cho (Seoul, KR); Nayoun Kim (Seoul, KR); Jung-Yeon Lim (Seoul, KR); Keon-Il Im (Seoul, KR); Young-Sun Nam (Seoul, KR)
C12N5/0636A61K35/17A61K39/12A61K39/235C07K16/246C07K16/28C12N5/0646A61K2039/5156A61K2039/5158C12N2501/2302C12N2501/24C12N2501/515C12N2501/998C12N2510/00C12N2710/10011C12N2710/16111C12N2710/16134Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,473,059
App. No.
15/769,872
Granted
Oct 18, 2022
Kind
B2
Abstract

The present invention relates to a method for inducing and proliferating target virus antigen-specific dual activated T cells, and can produce target virus antigen-specific dual activated T cells by treating monocytes, which are isolated from peripheral blood, with a cytokine and a virus antigen peptide mixture and culturing the same.

Claims (10)

1. A method for inducing and proliferating virus antigen-specific dual activated T cells comprising:

culturing peripheral blood mononuclear cells under IFN-γ and a virus antigen peptide mixture for 4 days to selectively induce virus antigen-specific dual activated T cells; and

proliferating the virus antigen-specific dual activated T cells under the presence of IL-2 and in the absence of anti-CD3 antibodies after the culturing step,

wherein the proliferated virus antigen-specific dual activated T cells comprise CD3+CD8+CD56-cells and CD3+CD8+CD56+cells.

2. The method of claim 1 , wherein the peripheral blood mononuclear cells are obtained from a normal person or a patient.

3. The method of claim 1 , wherein the IFN-γ is used at a concentration of 500 U/mL to 1,000 U/mL.

4. The method of claim 1 , wherein the IL-2 is used at a concentration of 200 U/mL to 1,000 U/mL.

5. The method of claim 1 , wherein the induction and proliferation of the dual activated T cells is carried out for a total of 20 days or more.

6. The method of claim 5 , wherein the induction and proliferation of the dual activated T cells is carried out for a total of 21 days.

7. The method of claim 1 , wherein the virus antigen comprises antigens selected from the group consisting of a cytomegalovirus (CMV), Epstein-Barr virus (EBV), an adenovirus (ADV), and BK virus (BKV).

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 29, 2019
From: THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION
To: LUCAS BIO CO. LTD.
Reel/Frame 050856/0569 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 20, 2018
From: CHO, SEOK GOO; KIM, NAYOUN; LIM, JUNG-YEON; IM, KEON-IL; NAM, YOUNG-SUN
To: THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION
Reel/Frame 045601/0839 →
Priority Claims (1)
KR 10-2015-0147584 · Oct 22, 2015 · national
Continuity (1)
Related Publication 20180305665A1 · Oct 25, 2018